Updates are available Correction dated 2022-01-12
Click to view Correction: https://doi.org/10.1038/s41586-021-04373-7
-
Authors
Kozareva, Velina
Martin, Caroline
Osorno, Tomas
Rudolph, Stephanie
Guo, Chong https://orcid.org/0000-0002-1230-5333
Vanderburg, Charles
Nadaf, Naeem
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Regehr, Wade G.
Macosko, Evan https://orcid.org/0000-0002-2794-5165
- License Information
-
More Information
Article History
Received: 3 March 2020
Accepted: 11 January 2021
First Online: 6 October 2021
Change Date: 12 January 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-021-04373-7
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until 31 August 2020, was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and ThermoFisher Scientific. From 1 August 2020, A.R. has been an employee of Genentech. For E.Z.M., the research herein was not done in his capacity as an MGH employee.
